Study on Tolerability of Levodopa/Carbidopa in Children With Angelman Syndrome

Access Programs

Disease Information

Descriptive Information
Brief Title † Study on Tolerability of Levodopa/Carbidopa in Children With Angelman Syndrome
Official Title † A Dose-escalation Tolerability Study of Levodopa/Carbidopa in Angelman Syndrome
Brief Summary This study is designed to determine the highest dose of levodopa/carbidopa that can be tolerated without any serious side effects by children with Angelman syndrome. It has been hypothesized that levodopa may lead to an improvement in the neurodevelopment and abnormal movements (e.g. tremors) in children with Angelman syndrome. Data from this study will be used to design a phase II trial to determine the efficacy of levodopa in treating children with Angelman syndrome.
Detailed Description Levodopa is a prodrug that "delivers" dopamine to the brain. It is usually given with carbidopa, a peripheral decarboxylase inhibitor, to increase the bioavailability of levodopa. Animal studies have suggested that levodopa can reverse the excess phosphorylation of some enzymes involved in synaptic and neuronal function, including calcium/calmodulin-dependent kinase type 2 (CaMKII). Recently, it was shown that excess phosphorylation of CaMKII may be responsible for some of the neurological deficits seen in Angelman syndrome. Therefore, it is hypothesized that levodopa may lead to an improvement in the neurodevelopment and abnormal movements (e.g. tremors) in children with Angelman syndrome. Although many children have used levodopa for a variety of medical conditions over the last 30 years, it has not been approved by the Food and Drug Administration (FDA) for use in children, and it has not been formally studied in children with Angelman syndrome, so we do not know what dose of levodopa is most appropriate for children with Angelman syndrome. Therefore, the purpose of this study is to find out the highest dose of levodopa that children with Angelman syndrome can tolerate without any serious side effects. Once we know the dose of levodopa that can be tolerated by children with Angelman syndrome, we will conduct a larger follow-up study to find out whether levodopa will lead to an improvement in their development and tremor.
Study Phase Phase 1
Study Type † Interventional
Study Design † Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary Outcome Measure † Maximum dose of levodopa/carbidopa that can be tolerated (without any dose limiting toxicity) by at least 5 out of 6 different subjects.
Secondary Outcome Measure †
Condition † Angelman Syndrome
Intervention † DrugLevodopa/Carbidopa (4:1)
Study Arms / Comparison Groups Levodopa/Carbidopa Other Names: Sinemet L-dopa Dosages are based on levodopa. Each cohort of 3 subjects will be placed on an increasing dose of levodopa (2, 5, 10, and 15 mg/kg/day) for 1 week, provided subjects in the preceding cohort tolerated the lower dose. Levodopa/Carbidopa is a combined formulation that will be dispensed as capsules. It should be taken 3 times a day.
Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status † Drug
Estimated Enrollment † 17
Start Date † January 2009
Completion Date June 2010
Primary Completion Date June 2010
Eligibility Criteria † Inclusion Criteria: - Angelman syndrome, confirmed by molecular testing - Must be willing to come for research visit on 2 days, exactly 1 week apart Exclusion Criteria: - On levodopa, carbidopa, or any dopamine agonists in the 2 weeks prior to participation - Other medical conditions that may be associated with developmental or cognitive delays - More than 2 clinical seizures per month - Used monoamine oxidase (MAO) inhibitors within the last 2 weeks - Used phenytoin within the last 2 weeks - Used phenothiazines, butyrophenones, and thioxanthenes within last 2 weeks - Hypersensitive to levodopa or carbidopa - Cardiovascular disease or instability - Respiratory diseases, including asthma, emphysema, chronic cough, and shortness of breath - Liver disease - Stomach or intestinal ulcers - Kidney disease - Hematological problems, including anemia, leucopenia, and thrombocytopenia - Used investigational drugs/interventions within the past three months
Gender Both
Ages 4 Years - 12 Years
Accepts Healthy Volunteers No
Contacts ††
Location Countries † United States
Administrative Information
NCT ID † NCT00829439
Organization ID 08-10-0490
Secondary IDs ††
Responsible Party Principal Investigator
Study Sponsor † Children's Hospital Boston
Collaborators ††
Investigators † Principal Investigator: Wen-Hann Tan, BMBS, Children's Hospital Boston
Information Provided By
Verification Date October 2012
First Received Date † January 26, 2009
Last Updated Date October 10, 2012
† Required WHO trial registration data element.
†† WHO trial registration data element that is required only if it exists.
Find a Clinical Trial
Related Videos
Free Newsletter